MA45112A - Auto-anticorps anti-pad4 comme marqueurs biologiques de réponse clinique pour le traitement de l'arthrite rhumatoïde - Google Patents
Auto-anticorps anti-pad4 comme marqueurs biologiques de réponse clinique pour le traitement de l'arthrite rhumatoïdeInfo
- Publication number
- MA45112A MA45112A MA045112A MA45112A MA45112A MA 45112 A MA45112 A MA 45112A MA 045112 A MA045112 A MA 045112A MA 45112 A MA45112 A MA 45112A MA 45112 A MA45112 A MA 45112A
- Authority
- MA
- Morocco
- Prior art keywords
- pad4
- antibodies
- auto
- treatment
- rheumatoid arthritis
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/978—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/10—Musculoskeletal or connective tissue disorders
- G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
- G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Rheumatology (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Rehabilitation Therapy (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662340560P | 2016-05-24 | 2016-05-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA45112A true MA45112A (fr) | 2019-04-10 |
Family
ID=59009670
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA045112A MA45112A (fr) | 2016-05-24 | 2017-05-23 | Auto-anticorps anti-pad4 comme marqueurs biologiques de réponse clinique pour le traitement de l'arthrite rhumatoïde |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US11613580B2 (https=) |
| EP (1) | EP3464358A1 (https=) |
| JP (2) | JP7217631B2 (https=) |
| AU (1) | AU2017270027B2 (https=) |
| CA (1) | CA3024910A1 (https=) |
| MA (1) | MA45112A (https=) |
| WO (1) | WO2017202879A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2017270027B2 (en) * | 2016-05-24 | 2024-07-11 | Medimmune Limited | Anti-PAD4 autoantibodies as clinical response biomarkers for the treatment of rheumatoid arthritis |
| CA3129624A1 (en) * | 2019-02-15 | 2020-08-20 | Inova Diagnostics, Inc. | Compositions and methods for diagnosing and assessing rheumatoid arthritis |
| US20210284744A1 (en) | 2020-03-15 | 2021-09-16 | Kiniksa Pharmaceuticals, Ltd. | Treatment of cytokine release syndrome with gm-csf antagonists |
| CN111458522B (zh) * | 2020-04-20 | 2024-01-09 | 杭州英邈生物科技有限公司 | 一种用于检测血浆白细胞介素6天然抗体的检测试剂、试剂盒及其应用 |
| CN111733151B (zh) * | 2020-07-13 | 2021-11-12 | 山东新创生物科技有限公司 | 一种基于padi4作为肿瘤标志物制得的抗原、抗体及应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5892019A (en) | 1987-07-15 | 1999-04-06 | The United States Of America, As Represented By The Department Of Health And Human Services | Production of a single-gene-encoded immunoglobulin |
| US6818406B2 (en) | 2001-03-23 | 2004-11-16 | Mayo Foundation For Medical Education And Research | Rheumatoid arthritis markers |
| CA2525179A1 (en) | 2003-05-08 | 2004-12-23 | Vanderbilt University | A gene equation to diagnose rheumatoid arthritis |
| PL1999152T3 (pl) | 2006-03-27 | 2013-05-31 | Medimmune Ltd | Element wiążący receptor GM-CSF |
| JP5252339B2 (ja) | 2007-12-25 | 2013-07-31 | 地方独立行政法人東京都健康長寿医療センター | Ｐａｄ４及び抗ｐａｄ４抗体の測定方法並びに関節リウマチの検出方法 |
| AU2010233926B2 (en) * | 2009-03-30 | 2014-01-16 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Biomarkers, methods and kits for the diagnosis of Rheumatoid Arthritis |
| WO2011066372A2 (en) | 2009-11-25 | 2011-06-03 | The Johns Hopkins University | Citrullination of human peptidylarginine deiminase 4 (pad-4) regulates its function and immunogenicity |
| EP2766394B1 (en) | 2011-10-10 | 2017-11-22 | Medimmune Limited | Treatment for rheumatoid arthritis |
| US8975033B2 (en) | 2012-11-05 | 2015-03-10 | The Johns Hopkins University | Human autoantibodies specific for PAD3 which are cross-reactive with PAD4 and their use in the diagnosis and treatment of rheumatoid arthritis and related diseases |
| EP3145541A1 (en) | 2014-05-19 | 2017-03-29 | Medimmune Limited | Treatment for rheumatoid arthritis |
| AU2017270027B2 (en) * | 2016-05-24 | 2024-07-11 | Medimmune Limited | Anti-PAD4 autoantibodies as clinical response biomarkers for the treatment of rheumatoid arthritis |
-
2017
- 2017-05-23 AU AU2017270027A patent/AU2017270027B2/en active Active
- 2017-05-23 WO PCT/EP2017/062479 patent/WO2017202879A1/en not_active Ceased
- 2017-05-23 EP EP17727829.8A patent/EP3464358A1/en active Pending
- 2017-05-23 MA MA045112A patent/MA45112A/fr unknown
- 2017-05-23 CA CA3024910A patent/CA3024910A1/en active Pending
- 2017-05-23 JP JP2018562123A patent/JP7217631B2/ja active Active
- 2017-05-23 US US16/304,055 patent/US11613580B2/en active Active
-
2023
- 2023-01-24 JP JP2023008716A patent/JP2023058524A/ja not_active Ceased
- 2023-02-14 US US18/169,205 patent/US20230303707A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA3024910A1 (en) | 2017-11-30 |
| JP2023058524A (ja) | 2023-04-25 |
| US20230303707A1 (en) | 2023-09-28 |
| US20200317793A1 (en) | 2020-10-08 |
| AU2017270027B2 (en) | 2024-07-11 |
| EP3464358A1 (en) | 2019-04-10 |
| JP2019523759A (ja) | 2019-08-29 |
| US11613580B2 (en) | 2023-03-28 |
| WO2017202879A1 (en) | 2017-11-30 |
| AU2017270027A1 (en) | 2018-12-06 |
| JP7217631B2 (ja) | 2023-02-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FR25C1001I2 (fr) | Compositions d'anticorps pour le traitement de tumeurs | |
| MA49279A (fr) | Compositions d'anticorps optimisées pour le traitement de troubles oculaires | |
| EP3661493A4 (en) | THERAPY PLANS FOR TREATMENT OF PAROXYSMALER NIGHTLY HEMOGLOBINURIA | |
| MA47719A (fr) | Esketamine pour le traitement de la dépression | |
| EP3359074A4 (en) | ELECTROPORATION FOR THE TREATMENT OF ADIPOSITAS OR DIABETES | |
| MA55697A (fr) | Molécules d'anticorps pour le traitement du cancer | |
| EP3494142A4 (en) | ANTI-SIGLEC-7 ANTIBODIES FOR TREATING CANCER | |
| MA45539A (fr) | Dihydropyranopyrimidines pour le traitement d'infections virales | |
| MA45050A (fr) | Polynucléotides codant pour la lipoprotéine lipase destinés au traitement de l'hyperlipidémie | |
| EP3645040A4 (en) | USE OF ANTI-FAM19A5 ANTIBODIES FOR CANCER TREATMENT | |
| MA45112A (fr) | Auto-anticorps anti-pad4 comme marqueurs biologiques de réponse clinique pour le traitement de l'arthrite rhumatoïde | |
| EP3645039A4 (en) | USE OF ANTI-FAM19A5 ANTIBODIES TO TREAT FIBROSIS | |
| EP3463341A4 (en) | AMINOACYLINDOL IMMUNOMODULATORS FOR THE TREATMENT OF AUTOIMMUNE DISEASES | |
| EP3630102A4 (en) | FORMULATIONS FOR TREATMENT OF POST-TRAUMATIC STRESS DISORDER | |
| MA56412A (fr) | Thérapie par l'arn messager pour le traitement des maladies articulaires | |
| EP3434291A4 (en) | COMPOSITION FOR THE TREATMENT OF BELTS | |
| MA45492A (fr) | Vecteurs viraux pour le traitement de l'hyperactivité vésicale neurogène | |
| EP3766497A4 (en) | Drug for treating cough | |
| EP3458079A4 (en) | COMPOSITIONS AND METHODS FOR TREATING ACNE | |
| MA55218A (fr) | Eskétamine pour le traitement de la dépression | |
| EP3384035A4 (en) | ASSAYS FOR THE DETECTION OF AAV-NEUTRALIZING ANTIBODIES | |
| EP3902826A4 (en) | USE OF ANTI-FAM19A5 ANTIBODIES TO TREAT ATHEROSCLEROSIS | |
| EP3393468A4 (en) | METHOD FOR TREATING AN IMMUNE WEAKNESS | |
| EP3716966A4 (en) | ALPHA-KETO ACID COMPOSITIONS FOR THE TREATMENT OF HYPOALBUMINEMIA | |
| EP3507703A4 (en) | DISTRIBUTED PLATFORM FOR THE RUGGED EXECUTION OF SMART HOME APPLICATIONS |